Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Carcinoma, Pancreatic Ductal 2Stomach Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 31Cisplatin 21pembrolizumab 8Fluorouracil 6Oxaliplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Taxes 4Albumin-Bound Paclitaxel 4pemigatinib 3infigratinib 3atezolizumab 3Specimen Handling 3Radiosurgery 3Platinum 3Magnetic Resonance Spectroscopy 3Leucovorin 3Carboplatin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2trametinib 2olaparib 2ivosidenib 2derazantinib 2cobimetinib 2Trastuzumab 2Radiotherapy 2Panitumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cholangiocarcinoma × PEGPH20 × Clear all
NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Halozyme Therapeutics

Phase 1 Terminated
85 enrolled 17 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡